Correlation Between Sumitomo Mitsui and CRISPR Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sumitomo Mitsui and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sumitomo Mitsui and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sumitomo Mitsui Financial and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Sumitomo Mitsui and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sumitomo Mitsui with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sumitomo Mitsui and CRISPR Therapeutics.

Diversification Opportunities for Sumitomo Mitsui and CRISPR Therapeutics

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Sumitomo and CRISPR is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Sumitomo Mitsui Financial and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Sumitomo Mitsui is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sumitomo Mitsui Financial are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Sumitomo Mitsui i.e., Sumitomo Mitsui and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Sumitomo Mitsui and CRISPR Therapeutics

Assuming the 90 days trading horizon Sumitomo Mitsui Financial is expected to under-perform the CRISPR Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sumitomo Mitsui Financial is 3.11 times less risky than CRISPR Therapeutics. The stock trades about -0.04 of its potential returns per unit of risk. The CRISPR Therapeutics AG is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  4,525  in CRISPR Therapeutics AG on July 27, 2025 and sell it today you would earn a total of  30.00  from holding CRISPR Therapeutics AG or generate 0.66% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Sumitomo Mitsui Financial  vs.  CRISPR Therapeutics AG

 Performance 
       Timeline  
Sumitomo Mitsui Financial 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Sumitomo Mitsui Financial has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Sumitomo Mitsui is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
CRISPR Therapeutics 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, CRISPR Therapeutics may actually be approaching a critical reversion point that can send shares even higher in November 2025.

Sumitomo Mitsui and CRISPR Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sumitomo Mitsui and CRISPR Therapeutics

The main advantage of trading using opposite Sumitomo Mitsui and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sumitomo Mitsui position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.
The idea behind Sumitomo Mitsui Financial and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes